Biofrontera AG
BFFTF · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $9 | $8 | $8 | $11 |
| % Growth | 15% | -0.8% | -25.4% | – |
| Cost of Goods Sold | $5 | $4 | $4 | $6 |
| Gross Profit | $4 | $3 | $4 | $5 |
| % Margin | 46.7% | 44.6% | 50.1% | 46.6% |
| R&D Expenses | $1 | $1 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $9 |
| SG&A Expenses | $8 | $8 | $9 | $9 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $9 | $9 | $9 | $9 |
| Operating Income | -$5 | -$5 | -$5 | -$4 |
| % Margin | -55% | -64.7% | -69.2% | -36.5% |
| Other Income/Exp. Net | -$1 | $5 | -$5 | $7 |
| Pre-Tax Income | -$6 | -$0 | -$10 | $4 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$6 | -$0 | -$10 | $4 |
| % Margin | -62.9% | -3.3% | -132.1% | 33.3% |
| EPS | -0.98 | -0.051 | -2.88 | 1.65 |
| % Growth | -1,840.6% | 98.2% | -274.5% | – |
| EPS Diluted | -0.98 | -0.051 | -2.88 | 1.65 |
| Weighted Avg Shares Out | 6 | 5 | 4 | 2 |
| Weighted Avg Shares Out Dil | 6 | 5 | 4 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $1 | $1 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$5 | $1 | -$9 | $4 |
| % Margin | -55% | 8.8% | -110.2% | 38.2% |